Finally, due to the scarcity of studies involving T-DXd in non-breast cancer patients, the pre-defined stratification factors (i.e., drug and cancer types) were insufficient to detect significant differences in the risk associated with distinct HER2-ADCs or cancer types. Here, ERBB2 is linked to breast carcinoma.